Tags

Type your tag names separated by a space and hit enter

Current Therapy in CKD Patients Can Affect Vitamin K Status.
Nutrients. 2020 May 30; 12(6)N

Abstract

Chronic kidney disease (CKD) patients have a higher risk of cardiovascular (CVD) morbidity and mortality compared to the general population. The links between CKD and CVD are not fully elucidated but encompass both traditional and uremic-related risk factors. The term CKD-mineral and bone disorder (CKD-MBD) indicates a systemic disorder characterized by abnormal levels of calcium, phosphate, PTH and FGF-23, along with vitamin D deficiency, decreased bone mineral density or altered bone turnover and vascular calcification. A growing body of evidence shows that CKD patients can be affected by subclinical vitamin K deficiency; this has led to identifying such a condition as a potential therapeutic target given the specific role of Vitamin K in metabolism of several proteins involved in bone and vascular health. In other words, we can hypothesize that vitamin K deficiency is the common pathogenetic link between impaired bone mineralization and vascular calcification. However, some of the most common approaches to CKD, such as (1) low vitamin K intake due to nutritional restrictions, (2) warfarin treatment, (3) VDRA and calcimimetics, and (4) phosphate binders, may instead have the opposite effects on vitamin K metabolism and storage in CKD patients.

Links

PMC Free PDF

Authors+Show Affiliations

Cozzolino M
Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.
Cianciolo G
Nephrology, Dialysis and Renal Transplant Unit, Department of Experimental Diagnostic and Specialty Medicine (DIMES), S. Orsola Hospital, University of Bologna, 40126 Bologna, Italy.
Podestà MA
Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.
Ciceri P
Renal Research Laboratory, Department of Nephrology, Dialysis and Renal Transplant, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Galassi A
Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.
Gasperoni L
Nephrology, Dialysis and Renal Transplant Unit, Department of Experimental Diagnostic and Specialty Medicine (DIMES), S. Orsola Hospital, University of Bologna, 40126 Bologna, Italy.
Manna G
Nephrology, Dialysis and Renal Transplant Unit, Department of Experimental Diagnostic and Specialty Medicine (DIMES), S. Orsola Hospital, University of Bologna, 40126 Bologna, Italy.

MeSH

CalciumFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHyperparathyroidismOsteocalcinPhosphatesRenal Insufficiency, ChronicRisk FactorsVascular CalcificationVitamin KVitamin K DeficiencyWarfarin

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32486167

Citation

Cozzolino, Mario, et al. "Current Therapy in CKD Patients Can Affect Vitamin K Status." Nutrients, vol. 12, no. 6, 2020.
Cozzolino M, Cianciolo G, Podestà MA, et al. Current Therapy in CKD Patients Can Affect Vitamin K Status. Nutrients. 2020;12(6).
Cozzolino, M., Cianciolo, G., Podestà, M. A., Ciceri, P., Galassi, A., Gasperoni, L., & Manna, G. (2020). Current Therapy in CKD Patients Can Affect Vitamin K Status. Nutrients, 12(6). https://doi.org/10.3390/nu12061609
Cozzolino M, et al. Current Therapy in CKD Patients Can Affect Vitamin K Status. Nutrients. 2020 May 30;12(6) PubMed PMID: 32486167.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current Therapy in CKD Patients Can Affect Vitamin K Status. AU - Cozzolino,Mario, AU - Cianciolo,Giuseppe, AU - Podestà,Manuel Alfredo, AU - Ciceri,Paola, AU - Galassi,Andrea, AU - Gasperoni,Lorenzo, AU - Manna,Gaetano La, Y1 - 2020/05/30/ PY - 2020/03/16/received PY - 2020/05/27/revised PY - 2020/05/28/accepted PY - 2020/6/4/entrez PY - 2020/6/4/pubmed PY - 2021/2/20/medline KW - chronic kidney disease KW - secondary hyperparathyroidism KW - vascular calcification KW - vitamin K KW - warfarin JF - Nutrients JO - Nutrients VL - 12 IS - 6 N2 - Chronic kidney disease (CKD) patients have a higher risk of cardiovascular (CVD) morbidity and mortality compared to the general population. The links between CKD and CVD are not fully elucidated but encompass both traditional and uremic-related risk factors. The term CKD-mineral and bone disorder (CKD-MBD) indicates a systemic disorder characterized by abnormal levels of calcium, phosphate, PTH and FGF-23, along with vitamin D deficiency, decreased bone mineral density or altered bone turnover and vascular calcification. A growing body of evidence shows that CKD patients can be affected by subclinical vitamin K deficiency; this has led to identifying such a condition as a potential therapeutic target given the specific role of Vitamin K in metabolism of several proteins involved in bone and vascular health. In other words, we can hypothesize that vitamin K deficiency is the common pathogenetic link between impaired bone mineralization and vascular calcification. However, some of the most common approaches to CKD, such as (1) low vitamin K intake due to nutritional restrictions, (2) warfarin treatment, (3) VDRA and calcimimetics, and (4) phosphate binders, may instead have the opposite effects on vitamin K metabolism and storage in CKD patients. SN - 2072-6643 UR - https://www.unboundmedicine.com/medline/citation/32486167/Current_Therapy_in_CKD_Patients_Can_Affect_Vitamin_K_Status_ DB - PRIME DP - Unbound Medicine ER -